Achilles Therapeutics PLC ADR • ACHL

Capital at risk.

About Achilles Therapeutics PLC ADR
Ticker
info
ACHL
Trading on
info
NASDAQ
ISIN
info
US00449L1026
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Iraj Ali Ph.D.
Headquarters
info
245 Hammersmith Road, London, undefined, United Kingdom, W6 8PW
Employees
info
204
Website
info
achillestx.com
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Metrics
BasicAdvanced
Market cap
info
$62.8M
P/E ratio
info
-
EPS
info
-$1.66
Dividend Yield
info
0.00%
Beta
info
1.25
Forward P/E ratio
info
0
EBIDTA
info
$-67.2M
Ex dividend date
info
-
Price & volume
Market cap
info
$62.8M
Average daily volume
info
1.6M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
0.59
Earnings
EPS
info
-$1.66
EPS estimate (current quarter)
info
-$0.41
EPS estimate (next quarter)
info
-$0.44
EBITDA
info
$-67.2M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.25
52-week High
info
$1.51
52-week Low
info
$0.63
50-day moving average
info
$1.30
200-day moving average
info
$1.01
Short ratio
info
0.23
Short %
info
1.90%
Management effectiveness
ROE (TTM)
info
52.12%
ROA (TTM)
info
30.17%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
41.1M
Float
info
20.8M
Insiders %
info
6.51%
Institutions %
info
86.10%
Analyst Insights & forecasts
info

0% Buy

0% Hold

100% Sell

Based on information from 1 analysts.

Average price target

info
$0.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.46
-$0.14
228.57%
Q4 • 23Beat
-$0.30
-$0.46
34.78%
Q1 • 24Beat
-$0.41
-$0.41
-
Q2 • 24Beat
-$0.48
-$0.48
-
Q3 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-16.4M
∞%
Q2 • 24
$0M
$-19.6M
∞%
Q3 • 24
NaN%
19.63%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$131M
$15.7M
11.98%
Q2 • 24
$123M
$19.5M
15.93%
Q3 • 24
6.49%
24.36%
32.99%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-17.3M
-
$0M
$-0M
Q2 • 24
-
-
-
-
Q3 • 24
-
-
NaN%
NaN%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Achilles Therapeutics PLC ADR share?
Collapse

Achilles Therapeutics PLC ADR shares are currently traded for undefined per share.

How many shares does Achilles Therapeutics PLC ADR have?
Collapse

Achilles Therapeutics PLC ADR currently has 41.1M shares.

Does Achilles Therapeutics PLC ADR pay dividends?
Collapse

No, Achilles Therapeutics PLC ADR doesn't pay dividends.

What is Achilles Therapeutics PLC ADR 52 week high?
Collapse

Achilles Therapeutics PLC ADR 52 week high is $1.51.

What is Achilles Therapeutics PLC ADR 52 week low?
Collapse

Achilles Therapeutics PLC ADR 52 week low is $0.63.

What is the 200-day moving average of Achilles Therapeutics PLC ADR?
Collapse

Achilles Therapeutics PLC ADR 200-day moving average is $1.01.

Who is Achilles Therapeutics PLC ADR CEO?
Collapse

The CEO of Achilles Therapeutics PLC ADR is Dr. Iraj Ali Ph.D..

How many employees Achilles Therapeutics PLC ADR has?
Collapse

Achilles Therapeutics PLC ADR has 204 employees.

What is the market cap of Achilles Therapeutics PLC ADR?
Collapse

The market cap of Achilles Therapeutics PLC ADR is $62.8M.

What is the P/E of Achilles Therapeutics PLC ADR?
Collapse

The current P/E of Achilles Therapeutics PLC ADR is null.

What is the EPS of Achilles Therapeutics PLC ADR?
Collapse

The EPS of Achilles Therapeutics PLC ADR is -$1.66.

What is the PEG Ratio of Achilles Therapeutics PLC ADR?
Collapse

The PEG Ratio of Achilles Therapeutics PLC ADR is null.

What do analysts say about Achilles Therapeutics PLC ADR?
Collapse

According to the analysts Achilles Therapeutics PLC ADR is considered a sell.